New first-line treatment for patients with metastatic pancreatic cancer
Approved by the Food and Drug Administration on February 13, 2024. NALIRIFOX, a combination chemotherapy for first-line treatment of metastatic pancreatic adenocarcinoma. Dr. Patrick BolandI am…
